EEG-pharmacological and neuropsychological study of (-)eburnamonine in patients with chronic cerebrovascular disorders

V. Manna, L. Conti, N. Martucci, A. Agnoli

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The effect of (-)eburnamonine in chronic cerebrovascular disorders has been evaluated with a neuropsychological methodology combined with a computerized EEG-pharmacological methodology. A two-part study was carried out in 8 patients with chronic cerebrovascular insufficiency: an acute treatment with (-)eburnamonine 40 mg intravenously and a chronic treatment with (-)eburnamonine 20 mg intravenously daily for 10 days and 60 mg orally daily during the 20 days following period. In the acute study, the modification of EEG power spectrum analysis - decrease of the delta and theta bands and increase of the alpha band - confirmed the drug passage through the blood-brain barrier and the influence of the drug on brain bioelectrical activity. In the chronic study, a statistically significant decrease in the delta band and in the theta band and a statistically significant increase in the alpha 2 band confirmed previous results. Concerning clinical and neuropsychological parameters, after 30 days of therapy, there was a decrease in the HRSD total score and an improvement in clinical symptoms, especially in mood depression, vigilance, cooperation and anxiety, as shown by PBRSM.

Original languageEnglish
Pages (from-to)740-751
Number of pages12
JournalCurrent Therapeutic Research
Volume32
Issue number5
Publication statusPublished - 1982

Fingerprint

Cerebrovascular Disorders
Electroencephalography
Pharmacology
Blood-Brain Barrier
Pharmaceutical Preparations
Spectrum Analysis
Therapeutics
Anxiety
Depression
Brain
eburnamonine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

EEG-pharmacological and neuropsychological study of (-)eburnamonine in patients with chronic cerebrovascular disorders. / Manna, V.; Conti, L.; Martucci, N.; Agnoli, A.

In: Current Therapeutic Research, Vol. 32, No. 5, 1982, p. 740-751.

Research output: Contribution to journalArticle

@article{b0410ac73a2549dd97fc464f39feed0a,
title = "EEG-pharmacological and neuropsychological study of (-)eburnamonine in patients with chronic cerebrovascular disorders",
abstract = "The effect of (-)eburnamonine in chronic cerebrovascular disorders has been evaluated with a neuropsychological methodology combined with a computerized EEG-pharmacological methodology. A two-part study was carried out in 8 patients with chronic cerebrovascular insufficiency: an acute treatment with (-)eburnamonine 40 mg intravenously and a chronic treatment with (-)eburnamonine 20 mg intravenously daily for 10 days and 60 mg orally daily during the 20 days following period. In the acute study, the modification of EEG power spectrum analysis - decrease of the delta and theta bands and increase of the alpha band - confirmed the drug passage through the blood-brain barrier and the influence of the drug on brain bioelectrical activity. In the chronic study, a statistically significant decrease in the delta band and in the theta band and a statistically significant increase in the alpha 2 band confirmed previous results. Concerning clinical and neuropsychological parameters, after 30 days of therapy, there was a decrease in the HRSD total score and an improvement in clinical symptoms, especially in mood depression, vigilance, cooperation and anxiety, as shown by PBRSM.",
author = "V. Manna and L. Conti and N. Martucci and A. Agnoli",
year = "1982",
language = "English",
volume = "32",
pages = "740--751",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - EEG-pharmacological and neuropsychological study of (-)eburnamonine in patients with chronic cerebrovascular disorders

AU - Manna, V.

AU - Conti, L.

AU - Martucci, N.

AU - Agnoli, A.

PY - 1982

Y1 - 1982

N2 - The effect of (-)eburnamonine in chronic cerebrovascular disorders has been evaluated with a neuropsychological methodology combined with a computerized EEG-pharmacological methodology. A two-part study was carried out in 8 patients with chronic cerebrovascular insufficiency: an acute treatment with (-)eburnamonine 40 mg intravenously and a chronic treatment with (-)eburnamonine 20 mg intravenously daily for 10 days and 60 mg orally daily during the 20 days following period. In the acute study, the modification of EEG power spectrum analysis - decrease of the delta and theta bands and increase of the alpha band - confirmed the drug passage through the blood-brain barrier and the influence of the drug on brain bioelectrical activity. In the chronic study, a statistically significant decrease in the delta band and in the theta band and a statistically significant increase in the alpha 2 band confirmed previous results. Concerning clinical and neuropsychological parameters, after 30 days of therapy, there was a decrease in the HRSD total score and an improvement in clinical symptoms, especially in mood depression, vigilance, cooperation and anxiety, as shown by PBRSM.

AB - The effect of (-)eburnamonine in chronic cerebrovascular disorders has been evaluated with a neuropsychological methodology combined with a computerized EEG-pharmacological methodology. A two-part study was carried out in 8 patients with chronic cerebrovascular insufficiency: an acute treatment with (-)eburnamonine 40 mg intravenously and a chronic treatment with (-)eburnamonine 20 mg intravenously daily for 10 days and 60 mg orally daily during the 20 days following period. In the acute study, the modification of EEG power spectrum analysis - decrease of the delta and theta bands and increase of the alpha band - confirmed the drug passage through the blood-brain barrier and the influence of the drug on brain bioelectrical activity. In the chronic study, a statistically significant decrease in the delta band and in the theta band and a statistically significant increase in the alpha 2 band confirmed previous results. Concerning clinical and neuropsychological parameters, after 30 days of therapy, there was a decrease in the HRSD total score and an improvement in clinical symptoms, especially in mood depression, vigilance, cooperation and anxiety, as shown by PBRSM.

UR - http://www.scopus.com/inward/record.url?scp=0020365134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020365134&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0020365134

VL - 32

SP - 740

EP - 751

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 5

ER -